Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-L1-IN-3 (Compound 4a) functions as an inhibitor targeting the PD-1/PD-L1 axis, with an IC50 value of 4.97nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1/PD-L1 interaction by binding to the PD-L1 dimer, obstructing PD-1 signaling. This compound is utilized in research pertaining to lung cancer and melanoma [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | PD-L1-IN-3 (Compound 4a) functions as an inhibitor targeting the PD-1/PD-L1 axis, with an IC50 value of 4.97nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1/PD-L1 interaction by binding to the PD-L1 dimer, obstructing PD-1 signaling. This compound is utilized in research pertaining to lung cancer and melanoma [1]. |
In vitro | PD-L1-IN-3 (Compound 4a) disrupts the interaction between PD-1 and PD-L1 at concentrations ranging from 0.01 to 100 μM over a period of 40 minutes, thereby enhancing TCR-mediated activation of Jurkat cells [1]. Additionally, PD-L1-IN-3 exhibits increased uptake in PD-L1-positive H358 tumors, with the level of uptake being proportional to the expression of PD-L1 [1]. |
Molecular Weight | 374.86 |
Formula | C19H16ClFN2OS |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-L1-IN-3 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 inhibitor inhibit